120 related articles for article (PubMed ID: 37800778)
1. Visual outcomes of early and late vitrectomy for breakthrough vitreous hemorrhage associated with exudative age-related macular degeneration and polypoidal choroidal vasculopathy.
Jirarattanasopa P; Khongsakdinasarn N; Ratanasukon M; Bhurayanontachai P; Dangboon Tsutsumi W
Medicine (Baltimore); 2023 Oct; 102(40):e35364. PubMed ID: 37800778
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Factors and Long-term Surgical Outcomes for Exudative Age-related Macular Degeneration with Breakthrough Vitreous Hemorrhage.
Kim TY; Kang HG; Choi EY; Koh HJ; Kim SS; Lee JH; Kim M; Byeon SH; Lee CS
Korean J Ophthalmol; 2020 Aug; 34(4):281-289. PubMed ID: 32783420
[TBL] [Abstract][Full Text] [Related]
3. Surgical outcomes of vitrectomy for breakthrough vitreous hemorrhage in eyes with exudative age-related macular degeneration.
Iwase T; Baba T; Saito Y; Nizawa T; Yokouchi H; Kubota-Taniai M; Kitahashi M; Yamamoto S
Int Ophthalmol; 2021 May; 41(5):1835-1844. PubMed ID: 33611763
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors of vitreous hemorrhage secondary to exudative age-related macular degeneration.
Hasegawa T; Otani A; Sasahara M; Gotoh N; Ooto S; Tamura H; Yamashiro K; Tsujikawa A; Yoshimura N
Am J Ophthalmol; 2010 Feb; 149(2):322-329.e1. PubMed ID: 20103057
[TBL] [Abstract][Full Text] [Related]
5. Clinical features and outcomes of breakthrough vitreous hemorrhage secondary to polypoidal choroidal vasculopathy.
Li MS; Tsen CL
PLoS One; 2022; 17(12):e0279778. PubMed ID: 36584198
[TBL] [Abstract][Full Text] [Related]
6. Visual outcomes of vitrectomy for polypoidal choroidal vasculopathy-related breakthrough vitreous haemorrhage.
Lin HC; Yang CH; Yang CM;
Eye (Lond); 2014 Jul; 28(7):797-806; quiz 807. PubMed ID: 24924445
[TBL] [Abstract][Full Text] [Related]
7. Results of vitrectomy for breakthrough vitreous hemorrhage associated with age-related macular degeneration and polypoidal choroidal vasculopathy.
Jung JH; Lee JK; Lee JE; Oum BS
Retina; 2010 Jun; 30(6):865-73. PubMed ID: 20182402
[TBL] [Abstract][Full Text] [Related]
8. Long-term Clinical Course after Vitrectomy for Breakthrough Vitreous Hemorrhage Secondary to Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy.
Kim JH; Kim JW; Kim CG; Lee DW
Sci Rep; 2020 Jan; 10(1):359. PubMed ID: 31941971
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.
Matsumiya W; Honda S; Kusuhara S; Tsukahara Y; Negi A
BMC Ophthalmol; 2013 Apr; 13():10. PubMed ID: 23557322
[TBL] [Abstract][Full Text] [Related]
10. THE INCIDENCE, CHARACTERISTICS, MANAGEMENT, PROGNOSIS, AND CLASSIFICATION OF BREAKTHROUGH VITREOUS HEMORRHAGE SECONDARY TO POLYPOIDAL CHOROIDAL VASCULOPATHY.
Zhao XY; Luo MY; Meng LH; Zhang WF; Li B; Wang EQ; Liu SZ; Yu WH; Chen YX
Retina; 2021 Aug; 41(8):1675-1685. PubMed ID: 33395221
[TBL] [Abstract][Full Text] [Related]
11. Differentiating Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy Using OCT B-Scan.
Kokame GT; Omizo JN; Kokame KA; Yamane ML
Ophthalmol Retina; 2021 Oct; 5(10):954-961. PubMed ID: 34022443
[TBL] [Abstract][Full Text] [Related]
12. Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy.
Kokame GT; deCarlo TE; Kaneko KN; Omizo JN; Lian R
Ophthalmol Retina; 2019 Sep; 3(9):744-752. PubMed ID: 31511169
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
[TBL] [Abstract][Full Text] [Related]
14. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
[TBL] [Abstract][Full Text] [Related]
15. Visual prognosis of submacular hemorrhage secondary to age-related macular degeneration: A retrospective multicenter survey.
Inoue N; Kato A; Araki T; Kimura T; Kinoshita T; Okamoto F; Murakami T; Mitamura Y; Sakamoto T; Miki A; Takamura Y; Matsubara H; Tsujinaka H; Gomi F; Yasukawa T
PLoS One; 2022; 17(7):e0271447. PubMed ID: 35862313
[TBL] [Abstract][Full Text] [Related]
16. Presenting characteristics and prevalence of polypoidal choroidal vasculopathy in Scandinavian patients with treatment-naïve exudative age-related macular degeneration.
Lorentzen TD; Subhi Y; Sørensen TL
Acta Ophthalmol; 2018 Aug; 96(5):475-480. PubMed ID: 29193780
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy.
Cheung CM; Li X; Mathur R; Lee SY; Chan CM; Yeo I; Loh BK; Williams R; Wong EY; Wong D; Wong TY
PLoS One; 2014; 9(6):e101057. PubMed ID: 24978485
[TBL] [Abstract][Full Text] [Related]
18. Using optical coherence tomography angiography in assessment of the anti-vascular endothelial growth factor effect for pathological vascular tissue in age-related macular degeneration and polypoidal choroidal vasculopathy.
Shen YS; Cheng CK
Eur J Ophthalmol; 2021 May; 31(3):1267-1280. PubMed ID: 32228025
[TBL] [Abstract][Full Text] [Related]
19. Improvements of Retinal Sensitivity after Intravitreal Injection of Aflibercept in Eyes with Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy.
Nizawa T; Kitahashi M; Baba T; Iwase T; Kubota-Taniai M; Hattori Y; Shiko Y; Kawasaki Y; Iwase T; Sato T; Ogawa S; Sugawara T; Yamamoto S
Ophthalmologica; 2021; 244(4):347-360. PubMed ID: 34015785
[TBL] [Abstract][Full Text] [Related]
20. Comparison of visual outcomes of polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration-up to 10 years of follow-up.
Park JY; Park YJ; Park SJ; Park KH; Yeo JH; Kim JG; Yoon YH; Lee JY; Woo SJ
Acta Ophthalmol; 2022 Dec; 100(8):e1579-e1588. PubMed ID: 35363434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
